Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
121.88
-0.75 (-0.61%)
At close: Jun 26, 2026, 4:00 PM EDT
116.88
-5.00 (-4.10%)
After-hours: Jun 26, 2026, 6:03 PM EDT
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
| Name | Position |
|---|---|
| Dr. Arturo M. Molina FACP, M.D., M.S. | Chief Medical Officer |
| Dr. Ashok Bhandari Ph.D. | EVP & Chief Discovery Officer |
| Dr. Dinesh V. Patel Ph.D. | CEO, President, Secretary & Director |
| Dr. Newman Yeilding M.D. | Executive VP, Chief Scientific Officer |
| Mr. Asif Ali | Executive VP & CFO |
| Mr. Carter J. King | Executive Vice President of Business Development |
| Mr. Matthew M. Gosling J.D. | Executive VP and Chief Legal & Business Officer |
| Mr. Venkat Thalladi Ph.D. | EVP & Chief Technical Officer |
| Ms. Abha Bommireddi | Executive VP & Chief of Staff |
| Ms. Carena Spivey | Executive VP & Chief Human Resources Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-18 | 8-K | tm2618251d1_8k.htm |
| 2026-05-05 | 8-K | tm2613550d1_8k.htm |
| 2026-05-05 | 10-Q | ptgx-20260331x10q.htm |
| 2026-04-28 | DEFA14A | tm261434d3_defa14a.htm |
| 2026-04-28 | DEF 14A | tm261434-1_def14a.htm |
| 2026-04-28 | ARS | tm262955d2_ars.pdf |
| 2026-02-25 | S-8 | tm266947d1_s8.htm |
| 2026-02-25 | 8-K | tm267184d1_8k.htm |
| 2026-02-25 | 10-K | ptgx-20251231x10k.htm |
| 2026-01-12 | 8-K | tm262863d1_8k.htm |